Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. (SPRO) on October 12, 2021, covering events that occurred on October 11, 2021. The filing addresses changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Jean-François Formela, M.D., resigned from the Board of Directors, the Compensation Committee, and the Nominating and Corporate Governance Committee effective October 11, 2021. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Kathleen Tregoning was appointed to the Board of Directors and the Compensation Committee effective October 11, 2021, to fill the vacancy created by Dr. Formela's resignation.
- Director Term: Ms. Tregoning will serve as a Class III Director until the Company's 2023 annual meeting of stockholders.
Outlook, Risks, and Management Commentary
The Board has determined that Ms. Tregoning is an independent director pursuant to Nasdaq listing standards. There are no arrangements or understandings between Ms. Tregoning and any other person regarding her appointment, and no material transactions requiring disclosure under Item 404(a) of Regulation S-K exist. Ms. Tregoning will receive standard non-employee director compensation pro-rated for the year and will enter into a standard indemnification agreement.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Kathleen Tregoning, against Nasdaq governance standards.
- Confirm the pro-rated compensation structure for Ms. Tregoning as outlined in the Company's Non-Employee Director Compensation Policy.
- Review the press release (Exhibit 99.1) for additional context on the Board composition changes.
- Note that this filing contains no financial updates; investors should refer to the most recent 10-K or 10-Q for financial health metrics.